Navigation Links
ESC announces review of Atrial Fibrillation Guidelines
Date:8/4/2011

The Guidelines Department of the European Society of Cardiology has issued the following statement today:

"The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial (a randomised dronedarone versus placebo outcomes study in patients with permanent atrial fibrillation and cardiovascular risk) because of adverse outcomes associated with dronedarone.

Current ESC Guidelines for the Management of Atrial Fibrillation (AF) recommend the use of dronedarone in patients with atrial fibrillation as an antiarrhythmic agent, to prevent recurrence of the arrhythmia and to reduce the ventricular rate in patients with non-permanent atrial fibrillation (strictly in accordance with the indications approved by the European Medicines Agency) and to prevent cardiovascular hospital admissions (in line with the FDA approved indication, and consistent with the data included within the Summary of Product Characteristics approved by the EMA).

The European Guidelines strongly advise against administration of dronedarone to any patient with NYHA Class III or IV or recently unstable (decompensation within the last 4 weeks) heart failure.

Both the EMA and FDA have advised that the use of dronedarone should be restricted to the approved indications, and that dronedarone should not be used in patients with permanent atrial fibrillation. The ESC Guidelines are consistent with this advice.

Both agencies are presently reviewing the benefit-risk of dronedarone and will issue new regulations for dronedarone in due course. The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory authorities have revised the labelling for dronedarone. The focused update of the AF Guidelines will also allow the incorporation of formal recommendations relating to the use of vernakalant, one or more of the new anticoagulant agents that are alternatives to warfarin, an
'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-489-872-044
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. Connecture, Inc. Announces Partnership with MedicareCRM
3. Chiquita Announces Support for School Salad Bar Campaign
4. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
5. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
6. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
7. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
10. Sunquest Announces Major Software Updates and Enhancements
11. Data Strategy Announces SurePath Services Offering for EMC Avamar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 The ... http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & Johnson’s ... bellwether trial, which is expected to get underway next ... in the U.S. District Court, Southern District of West ... be held on August 7, 2014 at 3:00 p.m. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... by Wright & Schulte LLC to provide consumers with ... can sometimes accompany use of the blood-thinning medication, as ... lawsuits pending in courts around the country. The ... anyone who may have suffered from life-threatening internal bleeding ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
... stigma is powerful, pervasive and destructive," said Marlene Schwartz, a ... reactions to two prom photos.// , One showed a ... woman. The other was the same photo altered to show ... ,The volunteers took a quick look at one or ...
... may be much more likely to have asthma and a nighttime ... from Australia.// ,Doctors often use night cough as a guide ... the August issue of Chest, suggest it may be appropriate to ... ,"Night cough is often taken as a sign of the onset ...
... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
... New research shows the same drugs you take to ... ,Researchers from the University of Pittsburgh followed more than ... than seven years. Results of the study show more ... cholesterol-lowering drugs developed breast cancer, while 2.1 percent of ...
... proved exercise reduces the risk of breast cancer, and now ... may lower a woman’s risk of developing breast carcinoma in ... into invasive breast cancer if left untreated. ,Researchers from ... 35 and 64 years old. More than 550 participants had ...
... Lung cancer is by far the biggest cancer killer around the ... survey researchers found that 38 percent of 626 patients they ... 61 percent of the black and 29 percent of the white ... air would cause it to spread., Most of the patients were ...
Cached Medicine News:Health News:False beliefs could cost cancer patients their lives 2
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Discovery 90SE Ultracentrifuge offers ... discover more. All the ... top-of-the-line performance, powerful functionality, ... use, all built into ...
... centrifuge continues to raise the standard for ... 1,048,000 x g performance and our new ... sample sizes from 0.2 ml to 8.3 ... direct drive, very quiet operation, rotor imbalance ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
Medicine Products: